Ripple joins MAS sandbox to test RLUSD trade flows
Ripple has joined the Monetary Authority of Singapore’s BLOOM initiative with Unloq to test programmable cross-border trade settlement using the XRP Ledger and Ripple USD.

Founder and CEO of Grafa, leading the company's vision to democratise financial data and empower investors with innovative tools.
Ripple has joined the Monetary Authority of Singapore’s BLOOM initiative with Unloq to test programmable cross-border trade settlement using the XRP Ledger and Ripple USD.
Australia is moving toward full-scale tokenised asset markets as the Reserve Bank of Australia shifts from research to implementation following its Project Acacia program.
The Ethereum Foundation has launched a dedicated hub outlining its roadmap to protect the network from future quantum computing threats, as development efforts accelerate.
New Zealand's Tower (ASX:TWR) appointed Simon Hoole as its Interim CFO, effective May 1.
PDD Holdings (NASDAQ:PDD) reported its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, revealing a narrative of steady top-line expansion tempered by the rising costs of its global ambitions.
Tuas (ASX:TUA) announced a 173% surge in statutory net profit after tax for the first half of FY26, reaching S$8.2 million.
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company pioneering the modulation of cortisol to treat severe disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli™ (relacorilant).
Energous (NASDAQ:WATT), a leading developer of RF-based wireless power networks, announced its financial results for the fiscal year ended December 31, 2025.
Kingsoft Cloud Holdings (NASDAQ:KC), an independent cloud service provider in China, announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on March 25, 2026.
Kiora Pharmaceuticals (NASDAQ:KPRX) released its fourth-quarter and full-year 2025 financial results on Wednesday, detailing a streamlined balance sheet and steady clinical momentum for its pipeline of retinal disease treatments.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy